Zhifei Biological and Merck Sign Revised Agreement to Enhance Strategic Cooperation

Zhifei Biological announced on April 2 that it has signed a revised and restated supply, distribution, and co-promotion agreement with Merck, effective April 2, 2026. According to Jin10, the original agreement will terminate upon the new agreement's activation. The revised agreement aims to deepen strategic cooperation between the two companies, enhance market coordination capabilities, and alleviate operational pressures. The agreement covers products including the nine-valent HPV vaccine, with the collaboration set to continue until the end of 2028, with an option to extend for two additional years. Zhifei Biological will dynamically adjust procurement and supply volumes based on market demand, with regular disclosures on the agreement's execution. The new agreement does not stipulate a base procurement amount for the products. Instead, Zhifei Biological and Merck will negotiate expected procurement and supply plans based on market demand forecasts and actual vaccination rates, with specific procurement details confirmed through written orders from both parties.